Zignol M, et al. - Considering the limitations of phenotypic testing for drug susceptibility hampering regular monitoring of the emergence of resistance to anti-tuberculosis drugs, researchers evaluated the use of genetic sequencing for surveillance of drug resistance in tuberculosis. They performed population-level surveys in hospitals and clinics in seven countries (Azerbaijan, Bangladesh, Belarus, Pakistan, Philippines, South Africa, and Ukraine) to evaluate the use of genetic sequencing to estimate the resistance of Mycobacterium tuberculosis isolates to rifampicin, isoniazid, ofloxacin, moxifloxacin, pyrazinamide, kanamycin, amikacin, and capreomycin. Findings suggested genetic sequencing as a valuable tool for surveillance of drug resistance. Before its widespread adoption for surveillance purposes, they recommend standardizing DNA extraction methods, recording and reporting nomenclature, and data interpretation.